| Autor: |
Muhammad Y. Jan, Sharon M. Moe, Oluwafisayo Adebiyi, Jeannie Chen, John Powelson, Heather N. Burney, Muhammad S. Yaqub, Dennis P. Mishler, Ranjani N. Moorthi, Tim E. Taber, Melissa D. Anderson, Yang Li, Xiaochun Li, Jonathan A. Fridell, William C. Goggins, Asif A. Sharfuddin |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Kidney International Reports. 7:1364-1376 |
| ISSN: |
2468-0249 |
| Popis: |
Hypotension after deceased donor kidney transplant (DDKT) is a risk factor for delayed graft function (DGF) and poor graft survival (GS). We hypothesize that vasopressin use in hypotensive DDKT recipients (DDKTRs) to increase blood pressure (BP) reduces DGF rates and is safe without increasing mortality.Group with vasopressin "study group" (Vasopressin group had lower mean maximum and minimum SBP and DBP in the operating room (OR). Median vasopressin start time post-DDKT was 2 hours (interquartile range [IQR] 1-6), and duration of use was 42 hours (IQR 24-63). DGF, creatinine at 1 year, and allograft biopsy rates were comparable. No deaths occurred during transplant hospitalization. Multivariable analysis did not find an effect of vasopressin use on GS.Treatment of hypotensive DDKTRs with vasopressin is safe and facilitated similar graft function and survival with that of nonhypotensive patients. In the absence of a randomized control trial, our study supports the safety of vasopressin therapy to prevent the adverse effects of hypotension. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
